1. Home
  2. SBGI vs LBRX Comparison

SBGI vs LBRX Comparison

Compare SBGI & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sinclair Inc.

SBGI

Sinclair Inc.

HOLD

Current Price

$14.15

Market Cap

998.0M

Sector

Industrials

ML Signal

HOLD

LBRX

LB Pharmaceuticals Inc

HOLD

Current Price

$29.30

Market Cap

850.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBGI
LBRX
Founded
1986
2015
Country
United States
United States
Employees
N/A
27
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
998.0M
850.5M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
SBGI
LBRX
Price
$14.15
$29.30
Analyst Decision
Buy
Strong Buy
Analyst Count
5
5
Target Price
$22.00
$46.60
AVG Volume (30 Days)
367.9K
146.2K
Earning Date
04-30-2026
05-06-2026
Dividend Yield
6.56%
N/A
EPS Growth
N/A
N/A
EPS
0.28
N/A
Revenue
$3,169,000,000.00
N/A
Revenue This Year
$12.37
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$50.29
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.89
$13.40
52 Week High
$17.88
$33.47

Technical Indicators

Market Signals
Indicator
SBGI
LBRX
Relative Strength Index (RSI) 50.64 53.07
Support Level $13.32 $26.44
Resistance Level $15.49 $33.47
Average True Range (ATR) 0.42 1.52
MACD 0.06 0.13
Stochastic Oscillator 83.64 74.81

Price Performance

Historical Comparison
SBGI
LBRX

About SBGI Sinclair Inc.

Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay-TV distributors.

About LBRX LB Pharmaceuticals Inc

LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.

Share on Social Networks: